What's Happening?
Biogen and Eisai are facing a three-month delay from the FDA regarding their application to initiate treatment with a subcutaneous formulation of their Alzheimer's therapy, Leqembi. The FDA has requested additional information, classifying the submission
as a major amendment, which has pushed the decision deadline from May 24 to August 24. Leqembi, initially approved in January 2023, is currently administered intravenously. The new subcutaneous version, Leqembi Iqlik, approved for maintenance treatments, offers a more convenient administration method. Biogen and Eisai aim to use this formulation for initial treatments, potentially eliminating the need for intravenous infusions. Analysts suggest the delay's impact is limited, as reimbursements for the drug are not expected until 2027.
Why It's Important?
The delay in the FDA's decision on the subcutaneous version of Leqembi could affect Biogen and Eisai's competitive positioning in the Alzheimer's treatment market. The approval of a more convenient, at-home treatment option could enhance patient adherence and expand market reach, especially against competitors like Eli Lilly's Kisunla, which offers a monthly infusion. The decision is crucial for Biogen's strategy to capture patients transitioning from Kisunla, as the convenience of subcutaneous administration could be a significant advantage. The delay adds uncertainty to Biogen's growth projections and could influence investor confidence.
What's Next?
Biogen and Eisai are expected to provide the additional information requested by the FDA to support their application. If approved, the subcutaneous formulation could become the first anti-amyloid therapy offering at-home dosing for the entire treatment duration. This approval would allow Biogen and Eisai to better compete on convenience and potentially capture a larger share of the Alzheimer's treatment market. The companies will likely continue to engage with the FDA to address any concerns and expedite the approval process.
